NTT-CORPORATION
22.7.2022 08:09:09 CEST | Business Wire | Press release
NTT Corporation (“NTT”) screened the “International Conference for Visualizing our Future brought about by Technological Innovation feat. IOWN” at the Short Shorts Film Festival & Asia 2022 (SSFF & Asia 2022), one of the largest international short film festivals in Asia recognized by the U.S. Academy Awards. The conference featured a discussion between NTT, experts of various fields, and international directors who have won the Grand Prix at SSFF & Asia about a vision of the future influenced by technological innovation like IOWN1 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005622/en/
After filmmakers from around the world watched the screening, NTT issued a call for short films featuring the theme of our ideal lives created alongside scientific and technological innovation. From the entries, we will create one short film that best captures the theme.
You can watch the conference on the official SSFF & Asia 2022 website .
NTT is working toward the realization of a smart society founded on IOWN, which is the next-generation communication platform. In November 2021, we founded the Natural Society Lab to communicate how the technology incorporating IOWN will benefit society and enrich people's lives. We also create short films to convey to the masses our vision of a world where innovation in science and technology flourish alongside ideal human life.
Experts and filmmakers that took part in the conference included the Yubari International Fantastic Film Festival Executive Producer and Shinichiro Kumagaya, a professor from the Research Center for Advanced Science and Technology at the University of Tokyo. The conference included discussions on the following four topics:
Part 1: What is "Natural Society Lab"?
Part 2: Natural Society Lab & Daily Life - in the Context of Film & Science
Part 3: Creators' Take on Visualizing Thought
Part 4: Expressing the World Realized by IOWN
Conference Speakers:
Akiko Kudo
NTT Senior Vice President
Head of Public Relations
and Deputy Head of Business strategy*
*2022.June
Junji Watanabe
NTT Communication Science Laboratories
Senior Distinguished Research Scientist
Shinichiro Kumagaya
Pediatrician and
Associate Professor at the Research Center
for Advanced Science and Technology
Shuichi Fukatsu
Executive Producer
for Yubari International Fantastic Film Festival
Kristof Deak
Filmmaker
Genevieve Clay-Smith
Filmmaker
The short films selected and produced through the competition will be released next year.
1
IOWN (Innovative Optical and Wireless Network)
A future communication platform utilizing cutting-edge optical-related technology and information processing technology to realize a smart world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005622/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom